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A B S T R A C T
Background: We aimed to review the burden and the potential impact of human papillomavirus (HPV) vaccines
on HPV-related diseases in the Republic of Korea and to discuss cervical cancer prevention practices in this
country.
Methods: Cancer burden statistics were retrieved from GLOBOCAN-2018 and Statistics Korea. HPV disease
burden was assessed via systematic review. Vaccine types relative contribution (RC) was estimated using data
from an international project using formalin-fixed paraffin-embedded specimens.
Results: Despite a downtrend in cervical cancer in recent years, Korean rates remain high. In contrast, or-
opharyngeal cancer incidence has gradually increased and other anogenital cancers remain rare.
In Korea, HPV prevalence in general population is around 20%. In cervical cancer, RC of HPVs 16/18 (74.0%)
increased to 92.0% when including HPVs 31/33/45/52/58. Limited information was available for other HPV-
related cancer sites.
Regarding prevention, since the inclusion of the HPV vaccine into the National Immunization Program, al-
most half (49%) of the target cohort in 2016 had received the first dose of vaccine. Further, percentage of women
screened with pap has increased from 41.1%-2009 to 53.0%-2016.
Conclusions: HPV-related disease burden in Korea is significant. Results suggest that the combination of effective
and high coverage HPV vaccination and screening programmes could substantially impact on HPV-related
disease in Korea.
1. Introduction
Cancer is the leading cause of death in the Republic of Korea
(hereinafter also referred to as Korea) and was responsible for 28.1% of
all deaths in 2017 [1]. In Korea, more than 277,000 new cancer cases
more than 86,000 new cancer deaths are reported annually (estimates
for 2018) [2]. Further, cancer burden is expected to increase in Korea
with an aging population and westernized lifestyles.
Human papillomavirus (HPV) infection is an important contributor
to cancer-related morbidity and mortality in the country, accounting for
11.3% of new infection-related cancer cases and 6.0% of infection-re-
lated cancer deaths in 2007 [3]. Although the majority of HPV infec-
tions (70–90%) do not cause symptoms and resolve spontaneously
within 2 years, persistent infection with oncogenic HPV types, also
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T
known as high-risk (HR) HPVs may lead to precancerous lesions and
cancers [4]. HR HPVs are not only responsible for virtually all cervical
cancers cases, but also causally related with a variable fraction of other
anogenital cancers (vulvar, vaginal, penile and anal) and a subset of
head and neck cancers, particularly base of tongue cancer, tonsil cancer
and other oropharyngeal cancer sites [4,5]. The last classification of the
International Agency of Research in Cancer (IARC) defined 12 HPV
types as carcinogenic to humans, namely HPVs 16/18/31/33/35/39/
45/51/52/56/58/59 (Group 1) [6]. Within them, HPV16 and HPV18
stand out for their highest carcinogenic capacity [6].
In recent years, several studies have examined the prevalence and
the burden of HPV-related diseases within the Korean population;
however, variations in the prevalence and type distribution have been
observed. Further, the arrival of the 4-valent HPV vaccine (Gardasil®) in
2007 and the 2-valent HPV vaccine (Cervarix™) in 2008 marked a
change in strategy in HPV prevention. Finally, the recent introduction
of the 9-valent HPV vaccine (Gardasil®9) could significantly impact on
HPV-related disease burden in Korea.
The aim of this review is therefore to provide an overview of the
global burden of HPV infection and HPV-related disease in Korea and to
estimate the potential public health impact of HPV vaccines on HPV-
related cancer in the country. In addition, we aimed to discuss current
cervical cancer preventive practices in the country. Special emphasis is
given to cervical cancer, as it accounts for more than 80% of cancers
attributable to HPV infection [7]. Consideration is also given to genital
warts, one major cause of morbidity worldwide, caused mainly by low-
risk (LR) HPV6 and HPV11.
2. Material and methods
The purpose of this review was to describe and discuss the state of
knowledge regarding the burden of HPV infection and HPV-related
disease in Korea.
Cancer burden statistics were retrieved from GLOBOCAN 2018
and from Statistics Korea [1,2]. Region-specific rates and information
regarding time trends were based on data from Statistics Korea and
from Cancer in Five Continents (CI5C Volume XI) [1,8]. The CI5C in-
cludes information from: a) Korea Central Cancer Registry (KCCR): The
KCCR began as a hospital-based nationwide cancer registry, initiated by
the Ministry of Health and Welfare in 1980. It is responsible for col-
lecting and managing nationwide cancer registry data, providing
technical and financial support to the regional cancer registries, pro-
viding training for cancer registers, and providing annual nationwide
cancer statistics; b) the following population-based regional cancer re-
gistries: 1. Busan Cancer Registry (BSCR), 2. Daegu Cancer Registry
(DCR), 3. Daejeon Cancer Registry (DJCR), 4. Gwangju Cancer Registry
(GCR), 5) Incheon Cancer Registry (ICR), 6) Jejudo Cancer Registry
(JCR), 7) Kangwha Cancer Registry (KCR), 8) Seoul Cancer Registry
(SCR), 9) Ulsan Cancer Registry (UCR).
A comprehensive search of peer-reviewed biomedical literature was
conducted to assess the burden of HPV-related disease and HPV type
distribution by using MEDLINE (1950 to present), Asian Pacific Journal
of Cancer Prevention (APJCP), KoreaMed Synapse (1933 to present)
and Google Scholar. Journal articles, reports, and various other types of
communication published between January 1933 and October 2018
pertaining to “HPV”, and “Korea” were considered. In addition, the
reference lists of retrieved articles were evaluated and included when
appropriate.
In addition, in order to assess the potential impact of the nine types
(HPVs 16/18/31/33/45/52/58/6/11) included in HPV vaccines (2-
valent, 4-valent and 9-valent) to HPV-related cancer cases in the Korean
population, we used data from an international project on HPV-related
lesions designed and coordinated by the Catalan Institute of Oncology
(ICO) (Barcelona-Spain) in collaboration with DDL Diagnostic
Laboratory (Rijswijk-Netherlands) [9–14]. Briefly, formalin-fixed par-
affin-embedded (FFPE) specimens from consecutive cases were
obtained from hospital pathology archives in 50 countries worldwide.
HPV DNA detection and typing was performed by polymerase chain
reaction (PCR) with SPF10 broad spectrum primers followed by DNA
detection using a DNA enzyme immunoassay (DEIA) and HPV geno-
typing using a reverse hybridization line probe assay (LiPA25) [15].
More detailed descriptions can be found in previous reports [9–14].
Specifically for Korea, the project includes information from 742 cases
of cervical cancer, 28 cases of female anal cancer, 16 cases of male anal
cancer, 10 cases of vaginal cancer, 23 cases of vulvar cancer, 28 cases of
penile cancer, 12 cases of female oropharynx cancer, 7 cases of male
oropharynx cancer and 3 cases of male larynx cancer. However, due to
the limited number of cases included for several locations, data were
supplemented using information from several countries in Eastern
Asia–including data from China, Japan, the Philippines, Thailand and
Taiwan. Prevalence was calculated as the proportion of women positive
for a given type among all tested samples. The relative contribution
(RC) of the types included in HPV vaccines was expressed as the pro-
portion of cases positive for a given type among all HPV DNA positive
samples. Type-specific information included information on multiple
infections, which were added to single types in accordance with a
proportional weighting attribution [16,17].
To complete the section of cervical cancer screening and HPV vac-
cination programme in Korea, the Korean Centre of Disease Control
(KCDC) and the Ministry of Food and Drug Safety (MSD Korea) were
consulted, together with other relevant publications.
3. Burden of HPV infection and HPV-related disease in Korea
3.1. HPV infection in women with normal cytological findings
HPV infection is commonly found in the anogenital tract of women
with and without clinical lesions. The most updated data estimating
HPV infection among women with normal cervical cytology is based on
systematic reviews and meta-analysis performed by the ICO/IARC
Information Centre on HPV and Cancer. Crude and adjusted prevalence
of HPV infection is estimated at 12.6% (12.3–12.9) and 10.7%
(10.4–10.9) in Eastern Asia [18].
However, limited data regarding specific HPV prevalence among
Korean women have been published. A meta-analysis conducted in
2008, reported crude and adjusted HPV prevalence of 20.4% and 23.9%
in Korean women with normal cytological findings [19]. Similar HPV
prevalence (21.9%) was observed in a recent retrospective cross-sec-
tional study among 18,815 women visited in 13 cities in Korea between
January 2014 and October 2015 [20]. However, substantial variations
are observed among individual studies (Table 1) – the largest Korean
study reported an overall HPV prevalence of 34.2% in women with
normal cytological findings [21]. These variations could be explained
by differences in HPV detection methods but also because some of these
studies have focused on women living in localized areas or on risk
groups; hence, are unlikely to be representative of all Korean women.
Globally, HPV prevalence in Korea peaks in women less than 25
year old (28.6%; 8.2–64.1), in which the majority of HPV infections
(70–90%) are asymptomatic and transient, and then declines to
10.0–12.0% in other age groups [22]. Individual studies agree with this
decrease with age [20,23–25].
Regarding HPV type distribution in women with normal cytological
findings, HPV16 is the dominant type in Korea, followed by HPVs 70/
58/52/66/18/56/51/35/68 in specific rank order, although differences
are observed from study to study [22] (Table 1). Particularly in Korea,
the prevalence of HPV52 (2.3%) and HPV58 (0.9%) was higher than in
other countries and regions [19].
3.2. HPV infection in women with cervical precancerous lesions
HPV DNA prevalence in Korea increases with lesion severity, in
accordance with Eastern Asia data. In Korea, Bae et al. [19] meta-
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analysis reported an adjusted HPV prevalence of 23.9% (23.8–24.1) in
women with normal cytology, 60.0% (59.5–60.2) in low-grade cervical
lesions (including ASCUS, low-grade squamous intraepithelial lesion
(LSIL) and cervical intraepithelial neoplasia grade 1 (CIN1)), 85.8%
(85.2–86.5) in high-grade cervical lesions (including high grade squa-
mous intraepithelial lesion (HSIL), CIN2/CIN3 and Carcinoma in situ
(CIS)) and 95.8% (95.4–96.2) in cervical cancer lesions.
This meta-analysis confirmed HPV16 as the most frequently de-
tected genotype in all stages of the disease. The strong enrichment in
HPV16 prevalence (6.0% in normal cytology, 20.0% in low-grade cer-
vical lesions, 40.6% in high-grade cervical lesions and 53.2% in cervical
cancer) confirms its higher carcinogenic potential compared to other
HPV types [19]. Even though, differences are observed among in-
dividual studies (Table 2).
3.3. Cervical cancer
3.3.1. Incidence and mortality rates
Current estimates indicate that every year 3348 women are diag-
nosed with cervical cancer and 1029 die from the disease in Korea
(estimates for 2018) [2]. This figure is similar to the 3582 cases (2015)
and 868 deaths (2017) recorded in the KCCR [1].
Based on crude incidence rates, cervical cancer ranks as the ninth
most frequent reported cause of cancer among females in Korea (13.1
new cases per 100,000 women in 2018), and the fourth among women
aged 15–44. Cervical cancer also ranks as the ninth most frequent re-
ported cause of cancer deaths among females in Korea (4.0 new deaths
per 100,000 women in 2018), and the third among women aged 15–44.
Age-standardized rates (ASR) in Korea (ASR-incidence (2018): 8.4 per
100,000 and ASR-mortality (2018): 2.0 per 100,000) were slightly
lower than that observed in Eastern Asia (ASR-incidence: 10.9 per
100,000 and ASR-mortality: 4.1 per 100,000) (Table 3) [2]. Similar to
other developed countries, decreasing trends in incidence and mortality
rates of cervical cancer have been reported in the country [1,8,26].
Cervical cancer age-specific incidence uniformly increases with age
in Korea, with 74.8% of cases reported in women aged 30–64 in 2015
[1]. By contrast, although cervical cancer mortality increases with age,
the peak in mortality is observed among women older than 50 years
(80.0% of cases in 2015) (Fig. 1).
In Korea, most of cases are squamous cell carcinomas (SCC) (ap-
proximately 80%) followed by adenocarcinomas (ADC), although an
increase in the proportion of ADC was reported (from 8.9% in 1993 to
16.1% in 2009). Unlike a downtrend in ASR-incidence of SCC (from
14.1 per 100,000 in 1993–7.0 per 100,000 in 2012), ASR-incidence of
ADC has remained fairly stable over time (Fig. 2) [1,26]. These could be
explained by several factors including duration and quality of screening
programmes and changes in cervical cancer risk factors, such as sexual
behaviour and HPV exposure.
In relation to carcinoma in situ, 62,300 cases (96.3% SCC) were
reported between 1993 and 2009. Unlike rates of invasive cervical
cancer, Korean rates of CIS have increased steadily over time across all
age groups (ASR-incidence has increased from 7.5 per 100,000 women
in 1993–19.0 per 100,000 women in 2009) [27].
3.3.2. HPV prevalence and type distribution
According to Bae et al. [19] meta-analysis, HPV16 is the main type
among cases of cervical cancer (53.2%), followed by HPV18 (11.9%)
and HPV58 (8.6%).
Similarly, pooled data on HPV prevalence estimated by ICO/IARC
Information Centre on HPV and Cancer reports HPV16 as the dominant
type in cervical cancer in Korea (56.3%, 53.9–58.6), followed by
HPV18 (11.7%, 10.2–13.3), HPV33 (4.7%, 3.8–5.9), HPV58 (3.7%,
2.9–4.8), HPV31 (2.5%, 1.7–3.4) and 45 (2.0%, 1.4–2.9). HPV16 is
detected more often in cases of SCC (59.3%, 56.3–62.1) than in cases of
ADC (36.5%, 30.7–42.7), while HPV18 and 45 are detected more often
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SCC (7.0%, 5.7–8.7% and 1.9%, 1.2–2.9, respectively) [22]. Variations
in prevalence and type distribution have been observed among in-
dividual studies (Table 2).
3.3.3. Survival
Population-based cancer survival estimates reflect the average
prognosis for a given cancer type, but data on cancer survival is scarce
in Korea. Data from the KCCR reports an overall 5-year relative survival
rate for all cancers increasing from 41.2% in 1993–1995, to 70.7% in
2011–2015. Specifically for cervical cancer, the 5-year relative survival
has remained quite stable since 1993, (77.5% in 1993–1995, to 80.0%
in 1996–2000, 81.4% in 2001–2005, 80.5% in 2006–2010 and 79.9%
in 2011–2015) [1]. These data are in accordance with SurCan database
[28].
Considerable variation in cervical cancer survival rates are observed
Table 3
Burden of cancer in anatomical sites related to HPV, in the Republic of Korea, compared to Eastern Asia.
Data sources: [2].
Republic of Korea Eastern Asia
N Crude ratea ASRa N Crude ratea ASRa
Cervix Incidence 3348 13.10 8.40 126,874 15.70 10.90
Mortality 1029 4.00 2.00 54,547 6.80 4.10
Anus Incidence Overall 334 0.65 0.34 6464 0.39 0.24
Female 182 0.71 0.35 3222 0.40 0.23
Male 152 0.59 0.34 3242 0.38 0.25
Mortality Overall 90 0.18 0.08 2900 0.18 0.10
Female 51 0.20 0.07 1104 0.14 0.08
Male 39 0.15 0.08 1796 0.21 0.13
Vagina Incidence 96 0.38 0.19 2121 0.26 0.16
Mortality 24 0.09 0.04 843 0.10 0.06
Vulva Incidence 143 0.56 0.28 4512 0.56 0.31
Mortality 35 0.14 0.05 1495 0.19 0.10
Penis Incidence 86 0.34 0.19 5082 0.60 0.39
Mortality 20 0.08 0.05 1792 0.21 0.13
Oropharynx Incidence Overall 735 1.40 0.81 10,195 0.62 0.39
Female 84 0.33 0.18 1914 0.24 0.14
Male 651 2.50 1.50 8281 0.98 0.64
Mortality Overall 176 0.34 0.18 4659 0.28 0.17
Female 17 0.07 0.03 763 0.09 0.05
Male 159 0.62 0.35 3896 0.46 0.29
Lip, Oral cavity Incidence Overall 1543 3.00 1.70 47,532 2.90 1.08
Female 594 2.30 1.20 16,458 2.00 1.20
Male 949 3.70 2.20 31,074 3.70 2.40
Mortality Overall 586 1.10 0.56 21,062 1.30 0.75
Female 225 0.88 0.36 7310 0.91 0.47
Male 361 1.40 0.08 13,752 1.60 1.00
Larynx Incidence Overall 1120 2.20 1.20 34,409 2.10 1.30
Female 50 0.20 0.09 3478 0.43 0.25
Male 1070 4.20 2.40 30,931 3.70 2.40
Mortality Overall 369 0.72 0.33 17,630 1.10 0.62
Female 43 0.17 0.06 2618 0.32 0.18
Male 326 1.30 0.69 15,012 1.80 1.10
“N”: number of cases; “ASR”: Age-standardized rate.

























Fig. 1. Age–specific incidence and mortality rates from cervical cancer in the
Republic of Korea, in 2015..
Data sources [1]
Fig. 2. Trends in cervical cancer incidence in the Republic of Korea, by his-
tology. “SCC”: Squamous cell carcinoma; “ADC”: Adenocarcinoma; “ASR”: Age-
standardized rate..
Data sources: Adapted from [1,26]
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across age, stage at diagnosis and histology in Korea. Five-year relative
survival is highest for localized disease (91.1%) and lowest for distant
stage cancers (25.8%) and remains consistent across age groups. With
regard to age at the diagnosis, 5-year relative survival is highest in
women aged 20–64 (> 90.0% for localized stage,> 70.0% for regional
stage and>30.0% for distant stage), and lowest in women aged 75 and
older (63.2% for localized stage, 48.6% for regional stage and 9.4% for
distant stage). In addition, 5-year relative survival is higher in SCC than
in ADC regardless of stage at diagnosis [26,29].
3.4. Other anogenital cancers and precancerous lesions
In addition to cervical cancer, HPV is responsible for a substantial
number of other anogenital cancers. Globally, low age-standardized
incidence rates are observed for these cancers in Korea (0.7 cases per
100,000), although data is still limited [7].
3.4.1. Anal cancer and precancerous lesions
Anal cancer is rare in the general population but is reported to be
increasing in more developed regions [7]. This is probably linked to
several risk factors such as changes in sexual behaviour that increases
the risk of HPV exposure in the anal canal [30]. An estimated 334 new
cases and 90 new deaths are diagnosed annually in Korea, with dif-
ferences by sex (estimates for 2018). Crude incidence and mortality
rates of anal cancer were 0.65 and 0.18 per 100,000, respectively. Age-
standardized incidence and mortality rates of 0.34 and 0.08 per
100,000 were observed in Korea, compared to 0.24 and 0.10 per
100,000 in Eastern Asia (Table 3) [2].
Anal cancer is similar to cervical cancer with respect to overall HPV
DNA positivity, with approximately 88.0% (85.1–91.0%) of anal cancer
cases and 95.3% (84.2–99.4%) of high-grade precancerous anal lesions
(AIN2/3) associated with HPV infection worldwide [12]. Worldwide,
HPV16 is the most common type in both lesions. Limited data is
available in Korea, with HPV prevalence in anal cancer ranging from
74.5% to 100.0% and with HPV16 being the dominant type [12,31,32]
(Table 4).
Regarding survival of anal cancer, data from a recent population-
based study in Korea showed that overall 5-year survival increased from
38.9% (period 1993–1995) to 65.6% (period 2006–2010) [33]. The
increase was consistent across histological types.
3.4.2. Vaginal cancer and precancerous lesions
Vaginal cancer is also a rare malignancy that shares similar risk
factors with cervical cancer. It is generally accepted that both carci-
nomas share the same aetiology of HPV infection although limited
evidence is available. Most vaginal cancers are classified as SCC
(90–95% of cases). An estimated 96 new vaginal cancer cases and 24
new deaths are diagnosed annually in Korea (estimates for 2018), with
crude incidence and mortality rates of 0.38 and 0.09 per 100,000
women, respectively. Age-standardized incidence and mortality rates in
Korea (0.19 and 0.04 per 100,000) were similar to those in Eastern Asia
(0.16 and 0.06 per 100,000) (Table 3) [2].
Worldwide, HPV DNA is detected among 74.3% (69.7–78.4) of va-
ginal carcinomas and 95.8% of high-grade vaginal intraepithelial neo-
plasia (VaIN2/3), with HPV16 being the most common type [11]. In-
formation at this cancer site is scarce in Korea, limited to one study that
estimated an HPV prevalence of 71.7% (57.5–82.7) in vaginal cancer
and 100.0% (77.2–100.0) in VaIN2/3, with HPV16 being the most
common type [11] (Table 4).
At the time of the review, no large-scale population-based studies of
incidence, mortality, or survival of vaginal cancer has been conducted
in Korea.
3.4.3. Vulvar cancer and precancerous lesions
Malignancies of the vulva are also rare among women worldwide.
About 60.0% of all vulvar cancer cases occur in more developed
countries. Regarding histology, basaloid/warty lesions generally affect
young women, and are very often associated with HPV DNA detection
(75–100%). Keratinizing vulvar carcinoma is the most frequent his-
tology (over 60%), occurs more often in old women and is more rarely
associated with HPV [34]. An estimated 143 new vulvar cancer cases
and 35 new deaths are diagnosed annually in Korea (estimates for
2018), with crude incidence and mortality rates of 0.56 and 0.14 per
100,000 women, respectively. In Korea, age-standardized incidence and
mortality rates were 0.28 and 0.15 per 100,000, compared to 0.31 and
0.10 per 100,000 in Eastern Asia (Table 3) [2].
Worldwide, HPV DNA is detected in 28.6% (26.5–30.8) of vulvar
carcinomas and 86.7% (84.0–89.4) in high-grade vulvar intraepithelial
neoplasia (VIN2/3), with HPV16 being the most common type [10].
Particularly in Korea, only one study estimated an HPV prevalence of
28.7% (22.7–35.6) in vulvar cancer and 100.0% (83.9–100.0) in VIN2/
3, with HPV16 being the most common type [10] (Table 4).
No population-based study of incidence, mortality or survival of
vulvar cancer has been conducted in Korea.
3.4.4. Penile cancer and precancerous lesions
Malignancies of the penis are rare among men worldwide. Incidence
rates are higher in less developed countries and generally affect men
aged 50–70. Over 95% of invasive penile cancers are SCC (subtypes:
49% keratinizing, 17% mixed warty-basaloid, 8% verrucous, 6% warty
and 4% basaloid). HPV is most commonly detected in basaloid and
warty tumours [34]. In Korea, an estimated 86 new penile cancer cases
and 20 new deaths are diagnosed annually (estimates for 2018), with
crude incidence and mortality rates of 0.34 and 0.08 per 100,000 men,
respectively. Age-standardized incidence and mortality rates in Korea
(0.19 and 0.05 per 100,000, respectively) were lower than those in
Eastern Asia (0.39 and 0.13 per 100,000, respectively) (Table 3) [2].
Worldwide, HPV DNA is detected in approximately 33.1%
(30.2–36.1) of all penile cancers and 87.1% (78.0–93.4) of high-grade
penile intraepithelial neoplasia (PeIN2/3), with HPV16 being the most
common type [13]. Particularly in Korea, only one study estimated an
HPV prevalence of 10.7% (2.3–28.2) in penile cancer and 100.0%
(29.2–100.0) in PeIN2/3, with HPV16 being the most common type
[13] (Table 4).
No population-based study of incidence, mortality or survival of
vulvar cancer has been conducted in Korea.
3.5. Head and neck cancer
Although smoking and alcohol consumption has been classically
regarded as the major etiological factors in head and neck cancers, HPV
has been recently found to cause an epidemiologically and clinically
distinct form of head and neck cancer, particularly at the oropharynx,
and to a weaker extent, oral cavity and larynx [34]. Moreover, the in-
cidence of HPV-related head and neck cancers is sharply increasing
worldwide, and is associated with lifestyle, including sexual behaviour,
and is rapidly changing in Korea from a “conservative Asian” to a more
open “Western” style.
Particularly in Korea, an estimated 735 new cases and 176 new
deaths are diagnosed annually at the oropharynx (estimates for 2018),
1120 new cases and 369 new deaths at the larynx, and 1543 new cases
and 586 new deaths at the lip and oral cavity, with differences by sex
(Table 3). Crude incidence and mortality rates at the oropharynx were
1.4 and 0.34 per 100,000 respectively, at the larynx were 2.2 and 0.72
per 100,000 respectively, and at the lip and oral cavity were 3.0 and 1.1
per 100,000 respectively. In Korea, age-standardized incidence and
mortality rates were 0.81 and 0.18 per 100,000 respectively, at the
oropharynx, 1.70 and 0.56 at the lip and oral cavity, and 1.20 and 0.33
at the larynx. In Eastern Asia, age-standardized incidence and mortality
rates were 0.39 and 0.17 per 100,000 respectively, at the oropharynx,
1.08 and 0.75 at the lip and oral cavity, and 1.30 and 0.62 at the larynx
[2].
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Regarding data retrieved from the KCCR for the period 1999–2009,
oropharyngeal cancer increased significantly over this period (annual
percent changes (APC) =2.4%), particularly in men aged 30–59 (APC
= 2.7%), whereas laryngeal and hypopharyngeal cancers markedly
decreased in both sexes. Interestingly, tongue cancer increased gradu-
ally 2.4% annually in both sexes [35].
Prior studies of head and neck cancers have reported higher in-
cidence rates [36]. However, a broader range of tumour sites was used
to define head and neck cancer (including larynx, oral cavity, or-
opharynx, hypopharynx, nasopharynx, trachea, oesophagus, nasal
cavity, and paranasal sinuses).
Globally, in oropharyngeal cancer, variations in HPV DNA detection
are observed among countries, with 25.0% (22.5–27.7) of cases attri-
butable to HPV. In oral cavity cancer and laryngeal cancer global HPV
DNA detection is 7.4% (6.0–8.9) and 5.9% (4.5–7.5) respectively [14].
At all these cancer sites, HPV16 is the most common type. Limited
studies have reported HPV prevalence in head and neck cancers in
Korea, ranging from 5.3% to 14.5% in the oral cavity, and from 23.5%
to 73.1% in the oropharynx, with HPV16 being the most common type
(Table 5) [14,37–41].
3.6. Genital warts
Genital warts are common and highly infectious lesions. Although
they are not life-threatening, the high infectivity, the high risk of re-
currence, and the need of multiple treatments, are associated with a
high social and economic impact [42]. Low risk HPV6 and HPV11 are
estimated to cause approximately 90.0% of genital warts [4].
Based on the update (until June 2016) of a systematic review of
global estimates performed by Patel et al. [43], overall reported an-
nual incidence of new genital warts ranged from 85 to 205 cases per
100,000 in both sexes combined (77–560 in men and 76–790 in
women, respectively), with higher incidence in people younger than
30 years (230–790 in both sexes combined, 130–560 in men and
320–1030 in women, respectively) [44]. Particularly in Korea, limited
data on the burden of genital warts is available. However, some es-
timates have been reported recently. A recent cross-sectional study
evaluated the prevalence and socio-economic burden of genital warts
using national claims data from the Health Insurance Review and
Assessment of Korea [45]. In this study the overall prevalence and
socio-economic burden of genital warts increased during the last 9
years (in 2015 was 11.6 and 3.6 per 100,000 men and women, re-
spectively), although significant differences were observed by sex. The
female prevalence increased until 2012 (highest in females aged
20–29), and decreased thereafter (APC = 3·6%). In contrast, the male
prevalence increased continuously over time (APC = 11·6%), espe-
cially in those aged 20–49 (Fig. 3). Variations in prevalence have been
reported in other Korean studies [46,47].
There is also limited Korean data regarding the prevalence of HPV
in genital warts. In a study examining the HPV prevalence in 150
consecutive male patients with histopathologic-confirmed genital warts
from a single private clinic, LR-HPV types were detected in 97.0% of
cases (only LR-HPV types in 76.5% of cases). In 121 cases (91.7%),
HPV6 or HPV11 or both were observed. HPV6 was the most common
type (76.5% globally, 50.8% as a single infection and 25.8% as multiple
infections) [48].
4. HPV screening and vaccination programme in Korea
4.1. Cervical Cancer Prevention Strategies in Korea
4.1.1. Cervical cancer screening programme
In Korea, the Pap smear was first introduced in 1988 in a health
examination for industrial workers [49]. In 1999, the National Cervical
Cancer Screening Programme (NCCSP) was launched as a part of the
National Health Care Screening Programme which supplied Medicaid
participants with stomach, breast and cervical cancer screening free-of-
charge [49]. The screening programme gradually expanded with in-
cluding further participants and target cancer sites. Currently, the
Korean government operates two population-based cervical screening
programmes. The National Health Insurance Service Cancer Screening
Programme (NHISCSP), which is offered to National Health Insurance
Service (NHIS) beneficiaries in the upper 50% income stratum, and the
National Cancer Screening Programme (NCSP), which is offered to
NHIS beneficiaries in the lower 50% income stratum and Medical Aid
Programme (MAP) recipients. Both programmes use the Pap test as the
main screening tool, that is conducted by gynaecologists and provide
complimentary biennial cervical cancer screening for all Korean women
over the age of 30 [50]. Since 2016, the programme has been expanded
to women over the age of 20 [51]. The percentage of women screened,
among target population, has increased rapidly, from 41.1% in 2009,
53.0% in 2016 [1,50,52].
4.1.2. National immunization programme (NIP) in Korea and current
guidelines for HPV vaccine use
In Korea, the 4-valent HPV vaccine (Gardasil®–VPHs 6/11/16/18)
was licensed for females aged 9–26 and males aged 9–15 in June 2007,
and expanded for females and males aged 9–26 in December 2011. The
2-valent HPV vaccine (Cervarix™–VPHs 16/18) was licensed for females
aged 9–25 in July 2008. In 2014, a 2-dose vaccination schedule was
approved for both vaccines for girls and boys aged 9–13 (4-valent HPV)
and for girls aged 9–14 (2-valent HPV). The 3-dose schedule was re-
served for older subjects and for immunocompromised subjects. In
addition, the 9-valent HPV vaccine (Gardasil®9–VPHs 6/11/16/18/31/
33/45/52/58) was approved by MFDS in January 2016 [53].
In June 2016, the HPV vaccine (2-valent and 4-valent) was included
in the NIP in Korea as a 2-dose schedule (0, 6 months) for 12 year old
girls (based on birth cohort). Girls have at least two years to get the
opportunity of being vaccinated within the NIP. The selection of the
HPV vaccine was based on physician or patient/parent preference [54].
4.2. Current status of HPV vaccination in Korea
Since the inclusion of the HPV vaccine into the NIP, 232,203 girls
received the first dose of HPV vaccine, which represented almost half
(49.9%) of the target cohort in 2016 (data February 2017) [55].
Fig. 3. Trends in genital warts prevalence in the Republic of Korea, by sex.
“APC”: annual percent change Adjusted to residence-registration mid-year po-
pulation in 2011..
Data sources: Adapted from [45]
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Regarding previous vaccination rates in Korea, a nationwide survey
on immunization rates conducted in 2013 (in cohorts born below 1993)
reported an HPV vaccine coverage of 28.7% between the ages of 19 and
26 years, 15.9% between 27 and 39 years, and 4.6% between 40 and 59
years [56]. In addition, vaccination is recommended by professional
societies, including the Korean Pediatric Society, the Korean Society of
Pediatric Infectious Diseases, the Korean Society of Obstetrics and Gy-
necology and the Korean Society of Gynecology Oncology.
4.3. Barriers and facilitators of HPV vaccination introduction in Korea
Globally, awareness and acceptance of vaccines in Korea (including
social, cultural, and behavioural barriers and facilitators) is relatively
high for childhood vaccines, although differences between NIP vs non-
NIP vaccines are observed. A nationwide survey conducted in 2012
among 4374 participants aged 7–83months showed 95.9–100.0%
vaccination rates for NIP vaccines, and 30.7–85.4% for non-NIP vac-
cines [57]. However, information in other age groups such as adoles-
cents is still scarce.
Regarding HPV vaccination in Korea, limited data is available prior
to the inclusion of the HPV vaccine into the NIP in 2016. However,
there are some vaccination data among hospital employees and re-
latives during reduced-price vaccination programmes. HPV vaccine
uptake increased from 2009 to 2010–2012 (370 and 515 subjects vac-
cinated, respectively) and was probably attributed to an increased
awareness of the benefits of the vaccine following media coverage and
education of health professionals. In contrast, a decrease was observed
in 2013 (17 women vaccinated during the programme) following the
safety issues of the HPV vaccine in Japan (June 2013). The negative
reports from the media could have significantly impact the acceptance
of HPV vaccination in Korea [58].
In addition, a nationwide survey conducted in 2007, and updated in
2016, showed a significant increase in the awareness of HPV infection
(from 13.3% in 2007 to 35.8% in 2016) and the preventive effect of the
HPV vaccine (from 8.6% to 36.9%), and a decrease in the willingness to
vaccinate against HPV (from 55.0% to 25.8%). Higher education level,
awareness of HPV infection and vaccination, and perception of the
seriousness of infection were positively associated with the willingness
of respondents to vaccinate their daughters [59,60]. Another nation-
wide survey in Korea revealed that mothers’ awareness of HPV vacci-
nation is the most important method for preventing cervical cancer in
their daughters. Further, in this study, mothers understood the im-
portance of undergoing the Pap test regardless the administration of the
HPV vaccine [61].
Previous to the inclusion of the HPV vaccine into the NIP in 2016, a
survey on the knowledge and acceptability of HPV infection and vac-
cination was performed among 140 mothers of children aged 9–14.
Sixty-six mothers (47.0%) were aware of HPV infection, 67 (48.0%) had
knowledge about HPV vaccinations, and 72 (51.0%) were aware of the
relation of HPV and cervical cancer. Further, most of them (99 mothers
- 70.0%) willed to vaccinate their daughters, referring protection
against cervical cancer as the main reason for vaccination (83 mothers).
Forty-one mothers had unfavourable opinions or strong opposition to
vaccinate their daughters, mainly related to concerns of possible side
effects (20 mothers), and poor awareness regarding HPV (18 mothers).
Higher education level was negatively associated with the willingness
to vaccinate their daughters, while knowledge of HPV and cervical
cancer was positively associated [62].
Fig. 4. Contribution of HPVs 16/11/18/31/33/45/52/58/6/11 in the Republic of Korea compared to Eastern Asia. “HPV”: Human papillomavirus; “95%CI”: 95%
Confidence Interval; * “9HPV types” includes the ones in 9–valent HPV vaccine: HPVs 16/18/31/33/45/52/58/6/11. Eastern Asia: combined data for the following
countries: China, Japan, Philippines, The Republic of Korea, Thailand and Taiwan. Type specific relative contribution estimations: Numerator = single infections +
proportional attribution of multiple types; Denominator = HPV DNA positive cancer cases..
Data sources [9–14]
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Finally, once the HPV vaccine was included into the NIP, the main
reason of the parents for not vaccinating their daughters with the HPV
vaccine was ‘worrying about safety’ (73.5% of respondents - mainly
those accessing information on HPV vaccine from media) [63].
5. Estimation of the potential impact of HPV vaccines in the
Korean population
5.1. Potential impact of HPV vaccines in cervical cancer in Korea compared
to Eastern Asia
According to data from an ICO international project on HPV-related
lesions [9–14], 90.8% (88.5–92.9) of Korean cervical cancer cases were
positive for HPV DNA. Among HPV DNA positive cases, HPV16 was the
most common detected type (RC: 65.3%, 61.6–68.9), followed by
HPV18 (RC: 8.8%; 7.3–11.2) and HPV33 (RC: 5.2%; 3.6–7.5). The
overall contribution of the combined HPVs 16/18 was 74.0%
(70.6–77.3); increasing up to 92.0% (89.7–93.9) with the inclusion of
HPVs 31/33/45/52/58/6/11. Further, the combined contribution of
the nine HPV types (HPVs 16/18/31/33/45/52/58/6/11) was similar
to that of the Eastern Asian region (p > 0.05) (Fig. 4).
5.2. Potential impact of HPV vaccines in anogenital cancers and head and
neck cancers in Eastern Asia
Due to the limited number of cases included for several HPV-related
cancer locations, Korean data were supplemented using information
from the following countries from Eastern Asia: China, Japan, the
Philippines, Thailand and Taiwan. Results from the ICO study indicate
that in Eastern Asia, HPV DNA prevalence was 89.5% (88.1–90.8) in
cervical cancer, 87.5% (61.7–98.4) in vaginal cancer, 38.5%
(25.3–53.0) in vulvar cancer, 82.1% (63.1–93.9) in female anal cancer,
81.2% (54.4–96.0) in male anal cancer, 9.6% (3.2–21.0) in penile
cancer, 21.4% (4.6–50.8) in female oropharyngeal cancer and 21.0%
(12.7–31.5) in male oropharynx cancer–with most cases identified as
SCC.
In females, the combined RC of the nine HPV types (HPVs 16/18/
31/33/45/52/58/6/11), among DNA positive cases, was 91.3%
Table 6
Relative contribution of HPVs 16/18/31/33/45/52/58/6/11 in HPV–related cancers positive for HPV–DNA, in Eastern Asia, by sex.
Data sources [9–14].
Female Male
Cervix Vagina Vulva Anus Oropharynx Anus Penis Oropharynx
N+=1805 N+=14 N+=20 N+=23 N+=3 N+=13 N+=5 N+=17




RC (%) (95%CI) RC (%) (95%CI) RC (%)
(95%CI)
RC (%) (95%CI) RC (%) (95%CI)
Combination of HPV types










HPVs 16/18 68.9 (66.7–71.1) 57.1
(28.9–82.3)






















HPV16 57.6 (55.3–59.9) 50.0
(23.0–76.0)




HPV18 11.3 (9.9–12.9) 7.1 (0.2–33.9) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
HPV31 3.2 (2.4–4.7) 0.0 (0.0–23.2) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
HPV33 3.9 (3.1–4.9) 7.1 (0.2–33.9) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 33.3 (0.8–90.6) 0.0 (0.0–24.7) 20.0 (0.5–71.6) 0.0 (0.0–19.5)
HPV45 4.9 (3.9–6.0) 0.0 (0.0–23.2) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 20.0 (0.5–71.6) 0.0 (0.0–19.5)
HPV52 5.3 (4.3–6.4) 7.1 (0.2–33.9) 10.0 (1.2–31.7) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
HPV58 5.0 (4.1–6.2) 0.0 (0.0–23.2) 10.0 (1.2–31.7) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 7.7 (0.2–36.0) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
HPV6 0.1 (0.0–0.3) 0.0 (0.0–23.2) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
HPV11 0.1 (0.0–0.3) 0.0 (0.0–23.2) 0.0 (0.0–16.8) 0.0 (0.0–14.8) 0.0 (0.0–70.8) 0.0 (0.0–24.7) 0.0 (0.0–52.2) 0.0 (0.0–19.5)
“HPV”: Human papillomavirus; “N+”: HPV–DNA positive cases; “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval; *“9 HPV types” includes the ones in
9–valent HPV vaccine: HPVs 16/18/31/33/45/52/58/6/11 ; ** “12 oncogenic HPV types” tested for were: HPVs 16/18/31/33/35/39/45/51/52/56/58/59/66/68.
Combined data for the following countries: China, Japan, Philippines, Republic of Korea, Thailand and Taiwan.
Type specific RC estimations: Numerator = single infections + proportional attribution of multiple types; Denominator = HPV DNA positive cancer cases.
Oral cavity and larynx cancer were not included due to the limited number of cases included in the study.
Fig. 5. Relative contribution of types included in HPV vaccines in HPV–related
cancers positive for HPV–DNA, in Eastern Asia. ”HPV”: Human papillomavirus;
“95% CI”: 95% Confidence Interval Combined data for the following countries:
China, Japan, Philippines, The Republic of Korea, Thailand and Taiwan.
Multiple infections are computed according to a proportional weighting attri-
bution. Type specific relative contribution estimations: Numerator = single
infections + proportional attribution of multiple types; Denominator = HPV
DNA positive cancer cases. Oral cavity and larynx cancer were not included due
to the limited number of cases included in the study..
Data sources [9–14]
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(89.9–92.6) in cervical cancer, 71.4% (41.9–91.6) in vaginal cancer,
65.0% (40.8–84.6) in vulvar cancer, 91.3% (72.0–98.9) in anal cancer
and 100.0% (29.2–100.0) in oropharyngeal cancer. In males, the RC of
the nine HPV types was 84.6% (54.6–98.1) in anal cancer, 80.0%
(28.4–99.5) in penile cancer and 100.0% (80.5–100.0) in orophar-
yngeal cancer (Table 6; Fig. 5).
In Eastern Asia, the combined RC of HPVs 16/18 was especially
prominent in anal cancer, for both females (91.3%; 72.0–98.9) and
males (76.9%; 46.2–95.0). The additional contribution of HPVs 31/33/
45/52/58 was especially prominent in cancer of the cervix (22.3%;
20.4–24.3), penis (40.0%; 5.3–85.3) and female oropharynx (33.3%;
0.8–90.6) (Table 6; Fig. 5).
6. Conclusions
HPV infection is an important contributor to cancer-related mor-
bidity and mortality in the Republic of Korea (11.3% of new infection-
related cancer cases and 6.0% of infection-related cancer deaths in
2007).
In June 2016, the HPV vaccine (2-valent and 4-valent) was included
in the National Immunization Programme in Korea as a 2-dose schedule
for girls12 year old. By 2016, 49.9% of the target cohort had received
the first dose of the HPV vaccine. The 9-valent vaccine has been li-
censed concurrently.
The inclusion of HPV vaccines in the Republic of Korea could impact
in HPV-related disease, preventing from 70% to 90% of cervical cancer
cases, most of anal and vaginal cancers, approximately a quarter of
vulvar cancers, a smaller fraction of penile and head and neck cancers
and more than 90% of benign genital warts.
However the impact of HPV vaccines on reducing the global burden
of HPV-related disease in Korea will greatly depend on HPV vaccine
uptake, coverage, availability, and affordability.
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